Form of Vitamin B3 Reduced Non-Melanoma Skin Cancer Occurrence


Nicotinamide, a form of vitamin B3, reduced the incidence of non-melanoma skin cancers among a group of high-risk patients, according to the ONTRAC study.

Ulcerated basal cell carcinoma

Ulcerated basal cell carcinoma; photo by Kelly Nelson

The use of nicotinamide, a form of vitamin B3, reduced the incidence of non-melanoma skin cancers by 23% among a group of high-risk patients, according to the results of the Australian ONTRAC study presented today at a presscast ahead of the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.

“Obviously we still need to use sunscreen and other skin cancer prevention strategies, but we now have an additional exciting opportunity for affordable skin cancer prevention, which we can instantly translate into clinical practice,” said Diona Damian, MBBS, PhD, a professor of dermatology at the University of Sydney, Australia, noting that the use of nicotinamide is recommended for high-risk patients and not for the general population.

The ONTRAC study included 386 high-risk patients defined as people who had at least two skin cancers in the last 5 years (average of 8). Patients were randomly assigned to nicotinamide at 500 mg or placebo for 12 months. According to Damian, nicotinamide actively provides skin cells with an “energy boost,” enhancing DNA repair and protecting the skin’s immune system from ultraviolet light. Patients were evaluated for new non-melanoma skin cancers every 3 months with new cancers confirmed using biopsy.

After 12 months, use of nicotinamide resulted in a relative rate reduction of 0.23 for non-melanoma skin cancer (95% confidence interval [CI], 0.04–0.38; P = .02) after adjustment for non-melanoma skin cancer history and study center. Nicotinamide also resulted in a relative rate reduction of 0.20 for basal cell carcinomas (95% CI, 0.06–0.39; P = .10) and 0.30 for squamous cell carcinomas (95% CI, 0.0–0.51; P = .05).

Damian said that a reduction in skin cancer was seen as early as the first 3-month visit and that the benefit was no longer seen after patients stopped taking the tablets at 12 months.

The researchers also evaluated if nicotinamide reduced actinic keratosis and found an 11% reduction in patients taking nicotinamide at 3 months (P = .01), a 14% reduction at 6 months (P < .001), a 20% reduction at 9 months (P < .0001), and a 13% reduction at 12 months (P < .005) compared with placebo.

Damian noted that nicotinamide is different from niacin, a different form of vitamin B3 that has a number of adverse effects like headaches, flushing, and low blood pressure, none of which were seen in patients taking nicotinamide.

Commenting on the results of this study, ASCO President Peter Paul Yu, MD, FACP, FASCO, said, “This is a very exciting prevention trial. You know we clamor for cancer prevention rather than treating the disease, and this is a major advance for us.”

Related Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Related Content